Bayer Pharmaceuticals Corp (BAYZF)

[smpathy4dadevil]

Bayer And Onyx Say 39% Progress On Phase III Nexavar Trial In Patients With Advanced Kidney Cancer - Quick Facts [BAY]

11/3/2005 4:19:02 AM Bayer Pharmaceuticals Corp. (BAY) and Onyx Pharmaceuticals, Inc. (ONXX) provided an update on the Nexavar Tablets Phase III trial in patients with advanced renal cell carcinoma or kidney cancer.

Based on announced interim analysis, there was an estimated 39% improvement in survival for patients receiving Nexavar versus those receiving placebo.

The final survival analysis, which is planned when 540 events have occurred, is not expected for some time. Therefore, while the findings of the interim analysis did not reach statistical significance, these early results suggest a favorable survival trend for patients who received Nexavar.

http://realtimetraders.com/sp/breakingnews.asp?vid=9625264